PercipEnz Releases OnCore Clinical and Translational Research Software, Version 10.0
This year’s release of the OnCore Clinical and Translational Research Software, Version 10.0, incorporates work done in eight collaborative projects with research organizations across the country.
“What we’re especially excited about with this version is bringing together the work that has been going on in several collaborative initiatives and making it available to all the OnCore centers,"said Anthony O’Hare, PhD, Chief Scientific Officer at PercipEnz Technologies, Inc., creators of OnCore.
Version 10.0 includes functionality that was previously only available to research centers who were participating in specific collaborative initiatives. New functionality in OnCore includes support for multi-center trials, a new Affiliate Network Administration portal, enhanced communication and reporting tools, and additions to the OnCore Software Developers Toolkit (SDK) for integration with other systems such as those for electronic IRB management.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.
